Business
Satellos Announces New Data Further Demonstrating Safety, Tolerability, and Functional Impact of SAT-3247 in First-in-Human Trial of Adults with Duchenne Muscular Dystrophy
Adults with Duchenne muscular dystrophy demonstrated functional improvements exceeding natural hi...
About this update from Satellos Bioscience Inc
[{"type":"text","content":"Satellos Announces New Data Further Demonstrating Safety, Tolerability, and Functional Impact of SAT-3247 in First-in-Human Trial of Adults with Duchenne Muscular Dystrophy\n\n\n .bwlistdecimal { list-style-type: decimal }\n.bwlistdisc { list-style-type: disc }\n \n\n\n\n\n\n Adults with Duchenne muscular dystrophy demonstrated functional improvements exceeding natural history, following 28-day treatment with SAT-3247\n \n\n\n\n\n\n Grip strength increased 118.6% and predicted forced vital capacity increased 5.8%; whereas, both decline in natural history\n \n\n\n\n\n\n SAT-3247 demonstrated safety, tolerability, and expected pharmacokinetics (PK) across all parts of Phase 1 a/b study\n \n\n\n\n\n\n New data presented in late-breaking poster session at the 30\n \n th\n \n Annual Congress of the World Muscle Society\n \n\n\n\n\n\n Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced new data further demonstrating tolerability and initial efficacy of SAT-3247 in adults (aged 20-27 years) with Duchenne muscular dystrophy (Duchenne or DMD) at the 30\n \n th\n \n Annual Congress of the World Muscle Society in Vienna, Austria.\n \n\n “Satellos’ new and updated clinical results from the 28-day clinical study in adults with Duchenne provide an important validation of SAT-3247’s potential to be a safe and clinically meaningful treatment,” said Frank Gleeson, co-founder and CEO of Satellos. “We are excited and confident in progressing into our next phase of clinical studies with the objective of demonstrating the transformative potential of SAT-3247 to the Duchenne community.”\n \n\n Data presented at the meeting demonstrate that SAT-3247 was safe and well-tolerated across the Phase 1a/b study with a desirable pharmacokinetic (PK) profile. The presentation also included new analyses of exploratory measures of early drug effect.\n \n\n Individuals treated with SAT-3247 over a 28-day period demonstrated an increase in grip strength far greater than seen in the Duchenne natural history in this age group. Specifically, a 118.6% mean improvement in maximum grip strength was observed in the dominant hand and 97.9% mean i...